Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Argus Health
McKinsey
Harvard Business School
Deloitte
Moodys
QuintilesIMS
Dow

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR DELTASONE

« Back to Dashboard

Clinical Trials for Deltasone

Trial ID Title Status Sponsor Phase Summary
NCT00323323 CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas Unknown status Bayer Phase 1 Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments. The biological response of lymphoma cells and the immune system to this drug combination will also be measured in patients before, during, and after therapy administration.
NCT00323323 CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas Unknown status Ohio State University Comprehensive Cancer Center Phase 1 Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments. The biological response of lymphoma cells and the immune system to this drug combination will also be measured in patients before, during, and after therapy administration.
NCT00550550 Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma.
NCT00562159 Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) Completed Merck Sharp & Dohme Corp. Phase 3 This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet.
NCT00801281 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Active, not recruiting Polish Lymphoma Research Group Phase 3 Evaluation of event free survival (EFS) of patients treated with the study chemotherapy induction program: R-CHOP compared to the standard R-CVP regimen and response rates, time to best response, PFS, OS, neutropenic fever rate, infection rate, change in Ig levels, change in lymphocyte subpopulations counts in previously untreated indolent lymphoma patients in need of systemic treatment.
NCT03023046 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Recruiting National Cancer Institute (NCI) Phase 2 This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Deltasone

Condition Name

Condition Name for Deltasone
Intervention Trials
B-Cell Non-Hodgkin Lymphoma 2
Rhinoconjunctivitis 2
Conjunctivitis 2
Rhinitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Deltasone
Intervention Trials
Lymphoma 9
Lymphoma, Non-Hodgkin 5
Lymphoma, B-Cell 5
Prostatic Neoplasms 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Deltasone

Trials by Country

Trials by Country for Deltasone
Location Trials
United States 51
Poland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Deltasone
Location Trials
Texas 3
Ohio 3
Massachusetts 3
New York 2
Illinois 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Deltasone

Clinical Trial Phase

Clinical Trial Phase for Deltasone
Clinical Trial Phase Trials
Phase 3 4
Phase 2/Phase 3 1
Phase 2 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Deltasone
Clinical Trial Phase Trials
Recruiting 7
Not yet recruiting 5
Completed 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Deltasone

Sponsor Name

Sponsor Name for Deltasone
Sponsor Trials
National Cancer Institute (NCI) 6
Incyte Corporation 2
Merck Sharp & Dohme Corp. 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Deltasone
Sponsor Trials
Other 15
Industry 11
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Queensland Health
Cantor Fitzgerald
Cipla
Colorcon
Healthtrust
Mallinckrodt
UBS
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.